These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11503757)

  • 1. Facsimile transmission of prescriptions for patients enrolled in hospice programs. Drug Enforcement Administration (DEA), Justice. Final rule.
    Fed Regist; 2001 Jan; 66(8):2214-5. PubMed ID: 11503757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1991 Jun; 56(106):25025-7. PubMed ID: 10111144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescriptions; dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration, Justice. Withdrawal of proposed rule.
    Fed Regist; 1983 Jun; 48(125):29713-4. PubMed ID: 10261481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(133):39611-4. PubMed ID: 18850676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare and Medicaid programs; programs of all-inclusive care for the elderly (PACE); program revisions. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2006 Dec; 71(236):71243-337. PubMed ID: 17171853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2008 May; 73(100):29685-8. PubMed ID: 18605404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare program; Medicare secondary payer (MSP) amendments. final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Feb; 73(36):9679-85. PubMed ID: 18389919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare program; changes to the hospital inpatient prospective payment system for acute care hospitals and fiscal year 2010 rates; and changes to the long-term care hospital prospective payment system and rate years 2010 and 2009 rates. Final rules and interim final rule with comment period.
    Centers for Medicare and Medicaid Services (CMS), HHS
    Fed Regist; 2009 Aug; 74(165):43753-4236. PubMed ID: 19827228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The regulatory process: impacting the NP's role.
    Wysocki S
    Nurse Pract Forum; 1992 Jun; 3(2):56-7. PubMed ID: 1392671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare program; e-prescribing and the prescription drug program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Nov; 70(214):67567-95. PubMed ID: 16273748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2007 rates; fiscal year 2007 occupational mix adjustment to wage index; health care infrastructure improvement program; selection criteria of loan program for qualifying hospitals engaged in cancer-related health care and forgiveness of indebtedness; and exclusion of vendor purchases made under the competitive acquisition program (CAP) for outpatient drugs and biologicals under part B for the purpose of calculating the average sales price (ASP). Final rules and interim final rule with comment period.
    Centers for Medicare and Medicaid Services (CMS), HHS
    Fed Regist; 2006 Aug; 71(160):47869-8351. PubMed ID: 16921666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2003 and inclusion of registered nurses in the personnel provision of the critical access hospital emergency services requirement for frontier areas and remote locations. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2002 Dec; 67(251):79965-80184. PubMed ID: 12510665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare and Medicaid programs: hospice conditions of participation. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Jun; 73(109):32087-220. PubMed ID: 18677823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schedules of controlled substances: rescheduling of the Food and Drug Administration approved product containing synthetic dronabinol [(-) - [DELTA] less than 9 greater than - (trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from schedule II to schedule III. Department of Justice (DOJ), Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1999 Jul; 64(127):35928-30. PubMed ID: 10558581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescriptions for Schedule II controlled substances: Drug Enforcement Administration, Justice. Notice of proposed rulemaking.
    Fed Regist; 1980 Apr; 45(70):24199-200. PubMed ID: 10246081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare program; establishment of the Medicare advantage program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4587-741. PubMed ID: 15678604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.